Sep. 10, 2014
The US-based Altor BioScience Corporation and Chinese Shenzhen Beike Biotechnology Co., Ltd. announced on September 10, 2014 that they have entered into a licensing agreement to develop and commercialize Altor’s ALT-803, a Interleukin-15 (IL-15) based superagonist complex, in China.
Under the terms of the agreement, Altor has granted Beike an exclusive license for the research, development, manufacture and commercialization of ALT-803 for therapeutic uses in all human disease indications in China. As part of the agreement, Altor will receive an up-front fee of US$4 million and could potentially receive over US$200 million in development and sales milestones, and tiered double-digit royalties based on sales of licensed products. Beike has also made a strategic equity investment of approximately US$5 million into Altor. Beike will have marketing rights for the licensed products in China, and Altor will retain marketing rights in all other countries.